PHOENIX, Ariz. — April 9, 2014 — Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen).
The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the potential spread of non-small cell lung cancer (NSCLC), according to the TGen study published online April 8 by the scientific journal Clinical & Experimental Metastasis.
NSCLC represents more than 85 percent of all lung cancers, which this year will kill an estimated 159,000 Americans, making it by far the leading cause of cancer-related death. It has a 5-year survival rate less than 10 percent.
The invasive and metastatic nature of NSCLC contributes to this high mortality rate, and so finding the cause of this potential to spread is key to helping patients survive.
Therapies targeting MET and FN14 are in clinical development, which could lead to treatments that could help halt or slow the spread of this lung cancer.
"As the metastatic phenotype is a major cause of lung cancer mortality, understanding and potentially targeting these pathways may reduce the high mortality rate in advanced lung cancer," said Dr. Timothy Whitsett, an Assistant Professor in TGen's Cancer and Cell Biology Division, and the study's lead author.
Significantly, the TGen study found that MET and FN14 were elevated in metastatic tumors compared to primary lung tumors and suppression of MET activation or FN14 expression reduced tumor cell invasion.
"The elevation of these receptors in metastatic disease opens the possibility for therapeutic intervention," said Dr. Nhan Tran, an Associate Professor in TGen's Cancer and Cell Biology Division, and the study's senior author.
Dr. Glen Weiss, Co-Unit Head of TGen's Lung Cancer Research Laboratory and Director of Clinical Research at Cancer Treatment Centers of America at Western Regional Medical Center, said, "This study identifies some targets that already have drugs in clinical trials, and helps put them into context for what might be a rational drug development approach for the treatment of this deadly cancer."
Other institutes that assisted with this study are: the University of Arizona; St. Joseph's Hospital and Medical Center; and Humboldt Medical Specialists.
The study, FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion, was funded by the National Institutes of Health, and grants from the St. Joseph's Foundation and the American Lung Association.
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: http://www.tgen.org.
TGen Senior Science Writer
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to http://www.cancercenter.com.
Director, Public Affairs
Cancer Treatment Centers of America®
14200 W. Celebrate Life Way, Goodyear, AZ 85338
O: (623) 207-3983
C: (602) 339-1569
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.